Sidhu, Jagdip S <br/><br/>
Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease.  [electronic resource] 

 -  American heart journal  Jun 2004 
 - e25 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-6744 
<br/><br/><label>Standard No.: </label>10.1016/j.ahj.2003.12.035  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Blood Platelets--metabolism<br/>Coronary Disease--blood<br/>Diabetes Complications<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Insulin Resistance<br/>Male<br/>Middle Aged<br/>P-Selectin--blood<br/>Platelet Activation--drug effects<br/>Platelet Count<br/>Receptors, Cytoplasmic and Nuclear--agonists<br/>Rosiglitazone<br/>Thiazolidinediones--pharmacology<br/>Transcription Factors--agonists